Cancer isn’t a single enemy. It’s a shapeshifter that learns your playbook faster than you can write it. But every now and then, someone walks into the lab, throws out the old rules, and says, what if we starve the disease instead of chasing it? That’s the energy coming out of Austin-based Faeth Therapeutics, a clinical-stage biotech that’s turning precision nutrition into what it calls the “4th pillar” of cancer treatment, right alongside surgery, radiotherapy, and traditional drugs.
Founded in 2019 by some of the biggest minds in oncology, Dr. Siddhartha Mukherjee, Dr. Lewis Cantley, Dr. Karen Vousden, Dr. Greg Hannon, and Dr. Scott Lowe, Faeth is led by Co-Founder & CEO Anand Parikh, JD, and Co-Founder & CSO Dr. Oliver Maddocks. Together, this crew isn’t just building treatments, they’re building a movement around metabolism as medicine. Their science says cancer’s hunger can be its weakness, and Faeth is serving up a new menu for survival.
Today, Faeth locked in a $25M strategic raise led by S2G Ventures, with existing backers Khosla Ventures, Future Ventures, Digitalis Ventures, KdT Ventures, and Cantos joining the table. New investors B Capital Group, Avicella, and THO Seed Fund also stepped in, because the data speaks volumes. In its Phase 1b study, the company’s PIKTOR regimen hit an 80% overall response rate in endometrial cancer patients, pushing median progression-free survival to 11 months vs the typical 3–4. In the Phase 2 DICE trial, Faeth’s sapanisertib combo cut disease progression risk by 34% and extended survival by 45% in platinum-resistant ovarian cancer. That’s not incremental progress, that’s a new beat in the rhythm of oncology.
Powered by its AI-driven MetabOS platform, Faeth matches tumor genotypes with therapeutic regimens and precision diets that choke out cancer’s metabolic lifelines. Their tech stack mixes machine learning, functional genomics, and digital patient tools that make therapy as intelligent as it is targeted. The new funding fuels the Phase 2 GOG-3111 trial in endometrial cancer and expands Faeth’s reach into inherited metabolic disorders like tyrosinemia type 1, proof that this model can move beyond oncology.
With Dr. Stephen Hahn, ex-FDA Commissioner, and Dr. Jayson Dallas, CEO of Rivus Pharmaceuticals, on the board, Faeth’s leadership isn’t just deep, it’s dangerous in the best way. When science, AI, and nutrition start speaking the same language, you don’t just treat disease, you outthink it.
